Govaert Klaas M, van Kessel Charlotte S, Lolkema Martijn, Ruers Theo J M, Borel Rinkes Inne H M
Curr Colorectal Cancer Rep. 2012 Jun;8(2):130-137. doi: 10.1007/s11888-012-0122-9. Epub 2012 Mar 17.
In patients with unresectable colorectal liver metastases (CRLM), radiofrequency ablation (RFA) might be a good alternative, whenever possible. In contrast to systemic therapy, the aim of RFA is to achieve complete local tumor control in an attempt to provide long-term survival. In this article we discuss the available evidence regarding the treatment of patients with unresectable CRLM, focusing on RFA in conjunction with modern systemic therapies. We observed that the available evidence in the existing literature is limited, and often consists of level 2 and 3 evidence, thereby hampering any firm conclusions. Nonetheless, RFA seems superior to chemotherapy alone in patients with liver-only disease amenable for RFA. However, the combination of RFA and chemotherapy has been demonstrated to be feasible and safe, lending support to the concept of RFA followed by chemotherapy, in order to reduce local recurrence rates and prolong survival.
对于无法切除的结直肠癌肝转移(CRLM)患者,射频消融(RFA)在可能的情况下可能是一种不错的选择。与全身治疗不同,RFA的目的是实现局部肿瘤的完全控制,以期提供长期生存。在本文中,我们讨论了关于无法切除的CRLM患者治疗的现有证据,重点是RFA联合现代全身治疗。我们观察到,现有文献中的现有证据有限,且往往由2级和3级证据组成,从而妨碍得出任何确凿结论。尽管如此,对于仅肝脏受累且适合RFA的患者,RFA似乎优于单纯化疗。然而,RFA与化疗联合已被证明是可行且安全的,这为RFA后进行化疗以降低局部复发率和延长生存期的概念提供了支持。